Xinjian Y. Liu
127 Dongming Road
Zhengzhou, China
Zhengzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study.
Journal: Annals of hematology
Published: May 10, 2022
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy.
Journal: Therapeutic advances in hematology
Published: October 12, 2021
Expression of PD-1, TIM-3, LAG-3 and BTLA in diffuse large B-cell lymphoma and its effect on prognosis
Journal: Zhonghua yi xue za zhi
Published: September 29, 2020
Effective Tacrolimus Treatment for Patients with Non-Severe Aplastic Anemia That is Refractory/Intolerant to Cyclosporine A: A Retrospective Study.
Journal: Drug design, development and therapy
Published: August 18, 2020
Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA.
Journal: Scientific reports
Published: July 15, 2020
Correction to: prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria.
Journal: Annals of hematology
Published: November 16, 2019
Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic stem cell transplantation for young patients with severe aplastic anemia - A meta analysis.
Journal: Leukemia research
Published: September 07, 2019
Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency.
Journal: Annals of hematology
Published: August 06, 2019
Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria.
Journal: Annals of hematology
Published: November 29, 2018
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Journal: Leukemia research
Published: April 15, 2017
Aberrant histone modification in CD19+ B cells of patients with chronic lymphocytic leukemia.
Journal: OncoTargets and therapy
Published: March 07, 2017
Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B‑cell lymphoma cells.
Journal: Molecular medicine reports
Published: March 23, 2015
Last Updated: 09/26/2026